In this June 2026 Mailbag, Jason and Jeff dive into OZEM, the world’s first actively managed GLP-1 weight-loss drug ETF, debating whether its steep fees are worth outsourcing your portfolio research. They also explore how generative AI is shifting white-collar labor, detail exactly how they would allocate a surprise $250,000 windfall, and answer a critical valuation question on why pre-revenue player QuantumScape still commands a multi-billion dollar market cap.

03:36 Baseball Trash Talk

04:21 Mailbag GLP-1 ETF OZEM

08:04 Active ETF Pros and Cons

15:39 AI Disruption Question

16:37 SaaS and AI Native Future

20:58 AI in Construction and Trades

22:33 AI Productivity vs Disruption

24:07 AI Makes Us Dumber

27:19 Solid Power Overview

29:20 Battery Tech Commoditization

33:43 Windfall Money Plan

39:22 Spending vs Investing Choices

42:07 QuantumScape Market Cap

Companies mentioned: ABNB, BMW, DAVA, F, GOOG, GOOGL, HIMS, KNSL, LEN, LLY, MELI, META, NOW, NVDA, NVO, PFE, PYPL, QS, RKLB, SLDP, TTD

Find where to listen & subscribe, portfolio contests, and contact information at https://investingunscripted.com

*****************************************

To get 15% off any paid plan at fiscal.ai, visit https://fiscal.ai/unscripted

Listen to the Chit Chat Stocks Podcast for discussions on stocks, financial markets, super investors, and more. Follow the show on Spotify, Apple Podcasts, or YouTube

*****************************************

Join our Patreon

Subscribe to our portfolio on Savvy Trader. Use code Unscripted2026 for 30% off a one-year subscription!

Learn more about your ad choices. Visit megaphone.fm/adchoices